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Simple Summary: Glioblastoma (GB) is an aggressive brain tumour with poor survival. Tumour
microenvironment is a key element in GB evolution and response to therapy. We assessed pres-
ence and phenotypes of microglia/macrophages in preclinical GL261-GB microenvironment under
Temozolomide (TMZ) treatment to unveil its possible relationship with MRSI-detected metabolomics
changes. Microglia/macrophage polarisation towards an anti-tumour phenotype prevailed in TMZ-
treated tumours. Since microglia/macrophages can represent 30–40% of the GB tumour volume, they
must contribute the metabolomic pattern change. PD-L1 expression also correlated with the anti-
tumour microglia/macrophage phenotype. These results highlight the potential of MRSI-detected
metabolomics as non-invasive biomarker for immune system action.
Abstract: Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy.
Previous work suggests that magnetic resonance spectroscopic imaging (MRSI) could act as a
biomarker of efficient immune system attack onto GB, presenting oscillatory changes. Glioma-
associated microglia/macrophages (GAMs) constitute the most abundant non-tumour cell type
within the GB and can be polarised into anti-tumour (M1) or pro-tumour (M2) phenotypes. One
of the mechanisms to mediate immunosuppression in brain tumours is the interaction between
programmed cell death-1 ligand 1 (PD-L1) and programmed cell death-1 receptor (PD-1). We
evaluated the subpopulations of GAMs in responding and control GB tumours to correlate PD-L1
expression to GAM polarisation in order to explain/validate MRSI-detected findings. Mice were
evaluated by MRI/MRSI to assess the extent of response to treatment and with qPCR for GAMs M1
and M2 polarisation analyses. M1/M2 ratios and PD-L1 expression were higher in treated compared
to control tumours. Furthermore, PD-L1 expression was positively correlated with the M1/M2 ratio.
The oscillatory change in the GAMs prevailing population could be one of the key causes for the
differential MRSI-detected pattern, allowing this to act as immune system activity biomarker in
future work.
Keywords: glioblastoma; orthotopic immunocompetent tumours; immune-enhancing metronomic
schedule; TMZ; magnetic resonance spectroscopic imaging; immune system activity imaging biomarker;
cancer immune cycle; glioma-associated microglia/macrophages; PD-L1
1. Introduction
Glioblastoma (GB) is the most frequent primary central nervous system malignancy
in adults. These tumours have poor prognosis, which has not significantly improved
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despite new diagnostic strategies and innovative therapies have been developed [1]. The
combination of chemotherapy (Temozolomide, TMZ) plus radiotherapy is still used as
the standard therapeutic choice after surgery, resulting in an average survival rate of
only 14.6 mo [2], which highlights the urgent need for investigating novel therapeutic
approaches/follow-up strategies in order to improve patient outcome. Nowadays, the
implication of the immune system in cancer surveillance and therapy response is widely
accepted [3]. This is especially relevant in GB, since GB cells have the capacity for creating
an immunosuppressive microenvironment and employ various methods to escape immune
surveillance through several pathways [4]. Therefore, understanding these strategies
and the biology of such tumour microenvironment will be helpful for developing novel
therapeutic approaches and follow-up methods, which should lead to improved prognosis
for GB patients.
Glioma-associated microglia/macrophages (GAMs), i.e., microglia, together with
peripheral macrophages recruited by tumour tissue from circulating blood [5], constitute
the most common non-tumour cell type in the GB microenvironment [6] and are charac-
terised by considerable diversity and plasticity. Over the last decade, it has become clear
that this cellular population interacts with numerous other cell types to actively influence
brain tumour biology [7]. These cells can be activated by various stimuli and polarised
into classically activated (M1) or alternatively activated (M2) phenotype, which repre-
sent extreme situations of a continuum of activation states. M1 microglia/macrophages
are usually involved in proinflammatory and anti-tumour mechanisms. In contrast, M2
microglia/macrophages are involved in activities for promoting tumour survival and
growth [8]. Accordingly, their gradual polarisation state determines the pathophysiological
character of this cell population, while subpopulations differ with respect to receptor
expression, effector function, and cytokine and chemokine production. The antitumor
effect of M1 microglia/macrophages was described to involve several mechanisms, such
proinflammatory cytokines release and activation of cytotoxic T lymphocytes. Indeed,
complex interactions between innate and adaptive immune responses such as antitumour
microglia/macrophages and T-cells have been described [9] and are key elements in sus-
tained therapy response. On the other hand, M2 microglia/macrophages can increase
the proportion of T-regulatory lymphocytes and lead to the inhibition of the cytotoxic
T-cell responses [10]. The fact that microglia/macrophages had been described to be more
abundant in GB than in low-grade gliomas [6] hints at their possible active role in glioma
progression. GAMs undergoing phenotype polarisation display changes in their molecular
and metabolic profiles, also triggering the expression of different markers such as Nos2 and
CD206 characterising M1 and M2 microglia/macrophages, respectively [11,12]. However,
more than a bilateral all or none option, the M1/M2 signature rather implies a continuum
between two extremes with specific abilities (e.g., epigenetic marks, metabolic reprogram-
ming) and local signalling (e.g., cytokines, chemokines, and immune checkpoints) [13].
Furthermore, one of the main mechanisms known to mediate immunosuppression in
the brain tumour microenvironment is the interaction between programmed cell death-1
ligand 1 (PD-L1) and its receptor (PD-1) [14]. PD-1 is an inhibitory receptor mainly ex-
pressed on activated T cells, B cells, macrophages, and dendritic cells, while PD-L1 is
highly expressed by malignant tumour cells [15], as well as by tumour-infiltrating myeloid
cells, including macrophages [16,17]. It is a notable immune checkpoint initially described
to cause T cell anergy [18], although its role in other cellular populations is still a matter
of discussion.
The preclinical GB model GL261 growing into C57BL/6 mice is widely accepted as
an immunocompetent model suitable for assessing therapeutic approaches and immune
system participation in therapy response [9,19–21]. Our group has studied the evolution
and behaviour of this tumour model under TMZ and other therapeutic approaches [22–25].
We have described the non-invasive assessment of response to therapy in preclinical GL261
GB (control and under TMZ therapy) with magnetic resonance spectroscopic imaging
(MRSI) approaches. MRSI combines anatomical information from magnetic resonance
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imaging (MRI) [26], and magnetic resonance spectroscopy (MRS), which provides infor-
mation regarding the metabolomic profile of the investigated tissue [27–29]. When using
MRSI is coupled to advanced machine learning analysis (source extraction as described
in [30]), spectral pattern differences between actively proliferating GB and GB respond-
ing to therapy can be shown colour-coded (the nosological images) in single-slice [23] or
multislice volumetric approaches [24]. Using volumetric MRSI-based nosological images,
we have defined the tumour responding index (TRI) as an evaluation parameter to esti-
mate/measure the extent of response to treatment. The level of detected response, TRI,
showed consistent oscillations with 6–7 day frequency during transient response to TMZ
therapy [24,31]. These oscillations were not detected regarding tumour volume changes.
We hypothesised that this could be a surrogate biomarker for immune system-contributed
local changes triggered by response to therapy, since this periodicity coincides with the
cancer immune cycle length described in [32], also supported by immunohistochemistry
data related to lymphocytes (CD3+) and microglia/macrophage (Iba1+) content [31].
The purpose of this work was to assess the origin of the oscillating pattern changes
spotted by MRSI in TMZ-treated/responding GL261 GB bearing mice under Immune-
Enhancing Metronomic Schedule (IMS) [31]. Since it was described that macrophages
can represent up to 30–40% of tumour masses [5], consistent with our results in [31], it is
reasonable to investigate whether the spectral pattern changes could be related to different
macrophage phenotypes present in such samples. Accordingly, we wanted to characterise
the different subpopulations of GAMs in MRSI-evaluated responding and control GL261
GB tumours by quantitative real-time polymerase chain reaction (qPCR). Furthermore,
PD-L1 gene expression was investigated by qPCR to correlate GAMs polarisation with
immunosuppression within the tumour microenvironment.
2. Materials and Methods
2.1. GL261 GB Preclinical Model Generation and Treatment
GL261 mouse glioma cells have been obtained from the Tumour Bank Repository at the
National Cancer Institute (Frederick, Maryland) and were grown as previously described
by us [33]. Cells were checked for mouse short tandem repeat (STR) profile as well as
interspecies contamination. In addition, PCR studies were performed in order to discard
mycoplasma and virus presence. All studies involving animals were approved by the
local ethics committee (Comissió d’Ètica en Experimentació Animal i Humana, CEEAH, www.
uab.cat/web/experimentacio-amb-animals/presentacio-1345713724929.html, accessed on
26 May 2021), according to regional and state legislations (protocol references CEA-OH-
9685/CEEAH-3665). Mice were purchased from Charles River Laboratories (l’Abresle,
France) and housed at the animal facility of the Universitat Autònoma de Barcelona. An
enriched environment was used, similar to the one described in [34], and mouse spent at
least three weeks in this environment prior to tumour implantation. In order to obtain
reproducible and well-categorised groups regarding tumour volume and evolution prior to
therapy and ensuring proper TRI and tumour volume for qPCR studies (see Sections 2.2.4
and 2.4), tumours were induced in a total of 110 C57BL/6 female wild-type (wt) mice by
intracranial stereotactic injection of 105 GL261 cells as already described by us [33]. Only 20
C57BL/6 mice (weighing 21.1 ± 1.5 g, aged 15.9 ± 3.3 weeks) fulfilling inclusion conditions
(e.g., TRI value, equal or higher than 60% for TMZ-treated mice and TRI = 0%, or as close
as possible, for control mice, see SM for further details) were eventually used for the
evaluation of the origin of the recorded MRSI patterns. Mice were weighed twice a week
and tumour volumes were followed up using T2 weighted image (T2w) MRI acquisitions.
Multi-slice MRSI studies (Section 2.2) were performed to assess the extent of the response
to treatment using the obtained nosological images. Tumour volumes were chosen aiming
to ensure enough volume to allow for proper MRSI acquisition and segmentation at the
desired time points, with no significant differences between groups.
GL261 GB treatment. For in vivo experiments, TMZ (Sigma-Aldrich, Madrid, Spain)
was dissolved in 10% dimethyl sulfoxide (DMSO) in saline solution (0.9% NaCl) and was
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administered using an oral gavage. Treated tumour-bearing mice (n = 10) received IMS-
TMZ 60 mg/kg, every 6 d (two or three times depending on the euthanasia day), from day
11 post-implantation (p.i.), as described in [31], while tumour-bearing control mice (n = 10)
received 10% DMSO vehicle following the same administration schedule.
2.2. In Vivo MRI and MRSI Studies
In vivo MRI/MRSI studies were conducted at the joint nuclear magnetic resonance
facility of the Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red-
Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) (Cerdanyola del Vallès, Spain), Unit
25 of NANBIOSIS (www.nanbiosis.es, accessed on 18 March 2021). Mice were positioned
in a dedicated bed, which allowed suitable anaesthesia delivery (isoflurane, 1.5–2.0% in
O2 at 1 L/min), with an integrated circuit of heating water for maintaining proper body
temperature. Respiratory frequency was monitored with the help of a pressure probe
and kept between 60–80 breaths/min. The 7T Bruker BioSpec 70/30 USR spectrometer
(Bruker BioSpin GmbH, Ettlingen, Germany) equipped with a mini-imaging gradient set
(400 mT/m) was used for acquisitions. A 72-mm inner-diameter linear volume coil was
used as transmitter, and a dedicated mouse brain quadrature surface coil was used as
receiver for MRI studies.
2.2.1. MRI Studies
GL261 GB-bearing mice were screened with high-resolution coronal T2w images using
a Rapid Acquisition with Relaxation Enhancement (RARE) sequence to evaluate brain
tumour presence and to monitor its evolution stage, using repetition time (TR)/effective
echo time (TEeff) = 4200/36 ms. The detailed set of parameters used in MRI acquisitions can
be found in Supplementary Material file. MRI data of tumour-bearing mice were acquired
and processed on a Red Hat Linux computer using ParaVision 5.1 software (Bruker BioSpin
GmbH, Ettlingen, Germany).
2.2.2. MRSI Studies
Consecutive point-resolved spectroscopy (PRESS), 14 ms echo time (TE) MRSI were
acquired individually across the tumour, using T2w high-resolution images as reference, as
described in [24]. Shimming was individually performed for each MRSI grid. MRSI grids
were spatially placed in order that the volume of interest (VOI) would include most of the
tumoral mass as well as part of the normal/peritumoral brain parenchyma. The whole set
of MRSI acquisition parameters can be found in the Supplementary Material file.
2.2.3. MRI and MRSI Processing and Post-Processing
• Tumour volume calculation
Abnormal brain masses observed in T2w images were manually segmented and each
tumour volume was calculated from T2w high-resolution horizontal images using the
following equation:
TV mm3 = [(AS1 × ST) + [(AS2 + ( . . . ) + AS10) × (ST + IT)]] × 0.0752 (1)
where TV is the tumour volume, AS is the number of pixels in the region of interest in
each MRI slice, ST is slice thickness, IT the inter-slice thickness, and 0.0752 accounts for the
individual pixel surface area in mm2. The tumour area was calculated from pixels in each
slice with ParaVision 5.1 software. The inter-slice volume was estimated through addition
of the inter-slice thickness to the corresponding slice thickness in Equation (1).
• Brain MRSI post-processing and machine learning strategies
MRSI data were post-processed as described by us in [35]. Briefly, data were ini-
tially pre-processed with ParaVision 5.1. Further post-processing was performed with
3D Interactive Chemical Shift Imaging (3DiCSI) software package version 1.9.17 (Cour-
tesy of Truman Brown, PhD, Columbia University, New York, NY, USA) for the fol-
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lowing: line broadening adjustment (Lorentzian filter, 4 Hz), zero-order phase correc-
tion, and ASCII format exportation. Then, dynamic MRSI processing module (DMPM,
http://gabrmn.uab.es/?q=dmpm, accessed on 26 May 2021), running over MatLab 2013a
(The MathWorks Inc., Natick, MA, USA), was used for spectral alignment within each
MRSI matrix, using the 3.21 ppm choline signal as reference). The 0–4.5 ppm region of each
MRSI spectrum was unit length normalised and exported in ASCII format used for pattern
recognition (PR) analysis. No baseline correction was performed in these spectra.
After that, spectral vectors were analysed following the methodology based in non-
negative matrix factorization (NMF) semi-supervised protocol described in [23] for clas-
sifying pixels into normal brain parenchyma, actively proliferating tumour and tumour
responding to treatment, and calculating nosologic maps representing the spatial response
to treatment. Green colour is used when the GB responding to treatment source contributes
the most, red for actively proliferating GB, blue for normal brain parenchyma, and black for
undetermined tissue. See Section 4.3 for further details about metabolites originating the
differences in the control or responding GB pattern metabolome (also SM and Figure S1).
2.2.4. Tumour Responding index (TRI) Calculations
In order to measure the extent of response to treatment using the obtained nosological





TRI is stated as the percentage of green (colour-coded), responding tumour pixels of
all grids over the total tumour pixels of all recorded grids.
Then, extreme values for TRI were selected, as homogeneously green/red as possible.
For TMZ-treated mice, tumours with TRI values >60% were selected while TRI = 0% (or
as close as possible) was selected for vehicle-treated mice. Regarding cases responding to
TMZ treatment, tumour volume meeting criteria for “stable disease” according to Response
Evaluation Criteria in Solid Tumors (RECIST) [36] adapted as described in [23] were chosen.
2.3. Animal Euthanasia
Whenever a mouse met criteria to be included in the study regarding MRI and MRSI
parameters, euthanasia was performed by cervical dislocation, and samples were dissected
and stored in liquid nitrogen.
2.4. RNA Isolation, cDNA Synthesis and qPCR
RNA isolation was performed following the protocol for purification of total RNA from
animal tissues (RNeasy Mini Kit, QIAGEN, GmbH, Hilden, Germany). RNA concentration
was quantified at 260 nm (Qubit, Thermo Fisher Scientific, Massachusetts, EEUU), and
RNA integrity and quality were determined with 260/280 and 260/230 ratios (NanoDrop,
München, Germany). One hundred ng of RNA from each sample was transcribed into
cDNA with the iScript cDNA synthesis kit (Bio-Rad, California, EEUU) according to
manufacturer’s instructions.
The qPCR amplification was carried out to investigate five genes: EGF-like module
containing mucin-like hormone receptor-like 1 (F4/80), inducible NO synthase (Nos2),
mannose receptor C type 1 (CD206) programmed cell death-1 ligand 1 PD-L1 (CD274
antigen), purchased from BioRad (California, EEUU, Ref 13,733; 18,126; 17,533; and 60,533,
respectively). F4/80 has been established as a global microglia/macrophage population
marker, Nos2 has been described as a marker of M1 phenotype, and CD206 has been
defined as a marker of M2 phenotype [37–40].
An amount of 2 ng of cDNA was used for qPCR, all reactions were performed twice,
and results were averaged. qPCR analysis was carried out using the Bio-Rad CFX qPCR
System. Primers and the Power SYBR Green Master Mix were purchased from Bio-Rad. The
PCR amplification reactions were performed in 10 µL reaction volumes, and PCR protocol
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consisted of 40 cycles of denaturation at 95 ◦C for 10 s and annealing/extension at 60 ◦C
for 30 s. Relative mRNA expression levels were normalised to two housekeeping genes
(tata binding protein (TBP) and hypoxanthine guanine phosphoribosyl transferase (HPRT),
purchased from BioRad (California, EEUU, Ref 21,374 and 15,452, respectively). Primers
sequences are described in the Supplementary Material file. The cycles threshold-values
(ct-values) average of the two reference genes for normalization purposes was used. For
each gene, the 2−∆∆Ct method [41] (a method to calculate relative gene expression levels
between different samples that directly uses the ct-values generated by the qPCR system)
for calculation was performed to analyse relative quantities.
2.5. Statistical Analysis
Sample distribution was assessed with Kolmogorov-Smirnov test. Levene’s test was used
for assessing variance homogeneity. A two-tailed Student’s t-test for independent measure-
ments was used for comparisons. Relationships between different markers were assessed with
the Pearson correlation coefficient. The significance level for all tests was p < 0.05.
3. Results
3.1. Follow up of GL261 Tumour-Bearing Mice and Endpoint Criteria
In this study, 20 mice were used (n = 10 IMS-TMZ-treated and n = 10 vehicle-treated).
The average tumour volume at therapy start (day 11 p.i.) was 7.5 ± 3.2 mm3 for TMZ-
treated mice and 9.1 ± 8.4 mm3 for control mice, with no significant differences between
both groups.
Tumour volume was followed up by MRI, and MRSI acquisitions were carried out
in order to measure the extent of response to treatment using the obtained nosological
images. Extreme values for TRI were searched for, as well as homogeneous response levels,
avoiding heterogeneous samples as much as possible. For TMZ-treated mice, MRSI studies
were performed when tumour volume showed decrease in comparison with previous
explorations, meeting criteria for “stable disease” according to adapted RECIST [23] (see
Supplementary Material file). The time point chosen for TMZ-treated mice was when
TRI values were equal or higher than 60%, and average TRI obtained was 76.97 ± 11.22%,
corresponding to intermediate/high response categories (see [24] for category definition).
The average tumour volume was 58.64 ± 26.43 mm3, at day 23.6 ± 1.6 p.i. For vehicle-
treated mice, the time point chosen for study was at the moment tumours showed TRI = 0%
(or as close as possible, average 4.59 ± 6.31%) and tumour had enough size to provide
samples for qPCR experiments (71.61 ± 29.18 mm3 at day 18.3 ± 3.8 p.i.). At chosen time
points, mice were euthanised by cervical dislocation, brain was removed, and tumour was
resected. All collected samples are described in Table S1, and tumour volume evolution is
shown in Figure 1.
3.2. Microglia/Macrophage Global Population, As Well As M1 and M2 Subtypes, Are Increased in
IMS-TMZ-Treated Tumours
In order to characterise the microglia/macrophage population in the GL261 GB mi-
croenvironment during TMZ treatment, gene expression level analyses were performed in
TMZ-treated and control mice: the F4/80 gene as general GAMs marker, Nos2 gene as M1
subtype marker, and CD206 gene as M2 subtype marker.
F4/80 gene showed significantly higher expression levels in TMZ-treated group than
in control group (p < 0.0001), with 0.71 ± 0.32 relative expression for treated tumours vs.
0.18 ± 0.08 for control tumours. The same trend was observed for Nos2 gene (0.05 ± 0.03
relative expression for treated tumours vs. 0.01 ± 0.01 for control tumours) and CD206
gene (0.23 ± 0.09 relative expression for treated tumours vs. 0.13 ± 0.06 for control
tumours), with significant differences (p = 0.0002 and p = 0.0073, respectively). Table 1
shows detailed description of gene expression levels and Figure 2 shows gene comparisons.
These results suggest that both M1 and M2 subtype populations may increase in TMZ-
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treated tumours when compared to vehicle-treated tumours, also supported by the larger
global microglia/macrophage population detected with the F4/80 gene expression level.




Figure 1. Tumour volume evolution (in mm3) of (A) responding TMZ-treated (n = 10) and (B) vehi-
cle-treated (n = 10) cases. In all responding cases, tumour volumes were in growth arrest, while in 
all control cases, tumour volume increased fast. Yellow shaded columns indicate TMZ administra-
tion days. The last point in the tumour volume evolution line designates the euthanasia day. The 
tumour volume at therapy start (day 11 p.i.) was 7.50 ± 3.22 mm3 for TMZ-treated mice and 9.07 ± 
8.44 mm3 for control mice. At the endpoint, the tumour volume was 58.64 ± 26.43 mm3 and the TRI 
was 76.97 ± 11.22% for TMZ-treated mice, while the tumour volume was 71.61 ± 29.18 mm3 and TRI 
was 4.59 ± 6.31% for control mice. C1458 (unique GABRMN mice identifier) is shown as an example 
of a responding TMZ-treated mouse, and C1474 is shown as an example of a control mouse. Noso-
logical images obtained from Grids 1–4 of case C1458 and Grids 1–3 of case C1474 were superim-
posed to the T2w-MRI. The tumour areas from the nosological images have been manually drawn 
over the tumour (shown in white line), and TRI was calculated from it. Rectangles over arrows at 
left indicate the cases and time points at which the MRSI-derived nosological images shown at right 
were acquired. 
3.2. Microglia/Macrophage Global Population, As Well As M1 and M2 Subtypes, Are Increased 
in IMS-TMZ-Treated Tumours 
In order to characterise the microglia/macrophage population in the GL261 GB mi-
croenvironment during TMZ treatment, gene expression level analyses were performed 
in TMZ-treated and control mice: the F4/80 gene as general GAMs marker, Nos2 gene as 
M1 subtype marker, and CD206 gene as M2 subtype marker. 
Figure 1. Tu our volume evolution (in mm3) of (A) responding TMZ-treated (n = 10) and (B) vehicle-
tr ated (n = 10) cases. In all responding cases, tumour v l mes were in g owth arrest, while in all
control cases, tumour volume increased fast. Yellow shaded columns indicate TMZ administration
days. The last poin in the tumour volume evolution line designates the euthanasia day. The tumour
volume at therapy start (da 11 p.i.) was 7.50 ± 3.22 mm3 for TMZ-treated mice and 9.07 ± 8.44 mm3
for control mice. At the endpoint, the tumour volume was 58.64 ± 26.43 mm3 and the TRI was
76.97 ± 11.22% for TMZ-treated mice, while the tumour volume was 71.61 ± 29.18 mm3 and TRI was
4.59 ± 6.31% for control mice. C1458 (unique GABRMN mice identifier) is shown as an example of a
responding TMZ-treated mouse, and C1474 is shown as an example of a control mouse. Nosological
images obtained from Grids 1–4 of case C1458 and Grids 1–3 of case C1474 were superimposed
to the T2w-MRI. The tumour areas from the nosological images have been manually drawn over
the tumour (shown in white line), and TRI was calculated from it. Rectangles over arrows at left
indicate the cases and time points at which the MRSI-derived nosological images shown at right
were acquired.
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Table 1. Relative normalised expressions obtained in qPCR studies with IMS-TMZ and IMS-vehicle-treated samples:
average ± SD of F4/80, Nos2, CD206, and PD-L1 genes, and ratios of M1/GAMs, M2/GAMs, and M1/M2. Significant
differences between groups are indicated by asterisks (*** p ≤ 0.001, ** p < 0.005, and * p < 0.05)).
Relative Expression
F4/80 *** Nos2 *** CD206 ** PD-L1 *** M1/GAMs M2/GAMs ** M1/M2 *
IMS-TMZ-treated 0.71 ± 0.32 0.05 ± 0.03 0.23 ± 0.09 1.07 ± 0.34 0.07 ± 0.02 0.35 ± 0.16 0.26 ± 0.16
IMS-vehicle treated 0.18 ± 0.08 0.01 ± 0.01 0.13 ± 0.06 0.46 ± 0.16 0.08 ± 0.05 0.84 ± 0.34 0.11 ± 0.09
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analysis (p = 0.0004), (B) M1 macrophage subtype population through Nos2 expression level analysis
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Moreover, we were also interested in assessing whether the increased levels of global
GAMs population would reflect predominant M1 or M2 subtypes. In order to gain more
insight into this question, correlation studies were performed with the aforementioned
markers F4/80, Nos2 and CD206. Pearson correlation showed significant values for
F4/80 vs. Nos2 expression levels in IMS-TMZ-treated samples (p = 0.0096), suggesting
a positive association (see Figure S2A). This association was not seen in vehicle-treated
samples, while CD206 expression was not significantly correlated with F4/80 in any of
the instances evaluated (see Figure S2B). These results suggest that the global GAMs
population biomarker increase observed in IMS-TMZ-treated tumours (ca. 4-fold) would
be mainly related to the increase in the M1 phenotype population and, to a lesser extent, to
the increase in the M2 phenotype population.
3.3. Assessing Different Macrophage Population Subtypes Regarding Global GAMs Values
Since the purpose of this work was to provide insight about the relationship between
microglia/macrophage subpopulations and the MRSI-sampled pattern in control and IMS-
TMZ-treated GL261 GB, M1/GAMs and M2/GAMs ratios were analysed (Figure 3A,B)
using the corresponding individual markers (F4/80, Nos2, CD206). Thus, in order to check
whether the predominant microglia/macrophage subtype population was different in
responding IMS-TMZ-treated and vehicle-treated samples, M1/M2 ratio was calculated
taking into account the relation of Nos2 gene to CD206 gene expression (Figure 3C). See
Table 1 for M1/GAMs, M2/GAMs, and M1/M2 ratio values. Results essentially show
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that there is indeed a change in the M1/M2 subtype proportions in GL261 tumours upon
response to treatment. A significantly higher ratio of M1/M2 microglia/macrophages
(p = 0.0249) was found in responding IMS-TMZ-treated tumours compared to vehicle-
treated tumours, while the ratio M1/GAMs showed no differences (p = 0.7944). This
apparent discrepancy can be explained when we take into account that both M1 sub
type and total GAM increase in responding tumours (Figure 2A,B). Furthermore, lower
M2/GAMs ratio (p = 0.0006) is also found in responding tumours. Even though M2s are
seen to increase in responding tumours (Figure 2C), this increase does not compensate for
the higher increase of total GAM, thus their ratio decreases (Figure 3B).
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Nos2 to F4/80, CD206 to F4/80 and Nos2 to CD206. No significant differences were observed
(p = 0.858) for the ratio of M1/GAMs between TMZ-treated (0.07 ± 0.02 M1/GAMs ratio) and
control (0.08 ± 0.05 M1/GAMs ratio) groups. On th other hand, significant differences were
found for M2/GAMs ratio (p = 0.001) and for M1/M2 ratio (p = 0.03) between TMZ-treated
(0.35 ± 0.16 M2/GAMs ratio and 0.26 ± 0.16 M1/M2 ratio) and control (0.84 ± 0.34 M2/GAMs ratio
and 0.11 ± 0.09 M1/M2 ratio) groups. Data are mean ± SD and significant differences between
groups are indicated by asterisks (** p < 0.005, * p < 0.05). Explanations for violin plots as in Figure 2.
Note that graphs are shown in different “y” scaling for better appreciation of data distribution.
3.4. PD-L1 Gene Is Highly Expressed in IMS-TMZ-Treat d Tumours, and These Increases May Be
Correlated with the Polarisation State of Microglia/Macrophage Population
The PD-L1 gene level expression was assessed, and values were compared between
IMS-TMZ-treated and vehicle-treated groups. Results suggest a significantly hig er PD-L1
gene expression in responding TMZ-treated tumours in comparison with control tumours
(p < 0.0001), with a 1.07 ± 0.34 relative expression found for TMZ-treated tumours and a
0.46 ± 0.16 relative expression for control tumours (see Figure 4A for visual comparison).
Furthermore, to investigate whether PD-L1 gene expression levels were correlated with
the polarisation state of GAMs, Pearson correlation analyses were performed, and PD-L1
expression level was shown to be positively correlated to the M1/M2 ratio (p = 0.0127)
(Figure 4B and Figure S2C), suggesting that for higher M1/M2 ratios, a higher PD-L1
expression level was found.
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4. Discussion
4.1. Immune System Populations Change during Response to Therapy
Duri g this work, samples from GL261 GB-bearing mice treated with IMS-TMZ
(n = 10) or vehicle (n = 10) were analysed by qPCR in order to characterise the mi-
croglia/macrophage population into the tumour site. Tumours were excised at chosen
time points, guided by the response level spotted by MRSI-based nosological images,
reflecting specific changes in their spectral pattern. Our results reinforce the idea of the mi-
croglia/macrophages role in tumour evolution: both control and treated tu ours presented
relevant microglia/macrophage content. Still, an overall in reas (ca. 4-fold change in
average) in such content was observed in IMS-TMZ-treated tumours responding to therapy,
through F4/80 gene level expression (Figure 2A). This trend is in line with previous Iba-1
immunohistochemistry data [31], which reported a 2.4-fold increase in the percentage of
Iba-1 stained area for TMZ-treated tumours (when narrowing groups to control vs. high
response cases, see [24,31] for further details). Since different methodological approaches
were used in [24,31] and in this work, direct comparison of results is not straightforward,
as already described by others [42], although the trend is clear.
Increased infiltration of immune cells into tumour sites after therapy and its relation-
ship with effective response ha been described for c ncer types ch a colorectal [43],
breast [44], ovarian [45], and brain [46], in agreement with results described in this work.
Immune infiltration has been described as a good prognostic factor, and certain chemother-
apeutic agents were described to actually enhance the host immune response through
presentation of tumour antigen peptides to T-cells, or upregulation of tumour antigens,
rendering these tumour cells more susceptible to immune system attack [47]. This is also
related to the corollary that effective therapeutic strategies should convert a ‘cold’ tumour
(noninflamed) with low immune cell infiltration into a ‘hot’ tumour (inflamed) with high
immune cell infiltrati n [48].
In our study, response to IMS-TMZ treatm nt ncreased the infiltrating microglia/macrophage
population. The beneficial effect of TMZ in preclinical/clinical settings was mainly at-
tributed to its effect as DNA alkylating agent and activation of the apoptotic cascade [49,50].
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However, it is worth noting that TMZ alone has a cytostatic rather than cytotoxic mech-
anism, when added to GL261 cultured cells at concentrations similar to the ones used in
preclinical studies, as described in [9,51–53]. Thus, the main beneficial effects observed
with TMZ therapy may have a different explanation. In this respect, the potential immuno-
genic effects of TMZ are gaining prominence [9,54–58]. Through the release/exposure
of immunogenic signals, TMZ administration may launch the cancer immune cycle as
described by Chen and Mellman [59], eventually leading to tumour cell killing. On the
other hand, it was also described that DNA damage repair (DDR) mechanisms triggered
after TMZ exposure could lead to reprogramming of macrophages to a tumor-supportive
state (M2) and TMZ-resistant cells would display upregulated DDR cytokines (preclini-
cal and database human samples) [60], in line with overall results described in [61] with
GL261 cells. Hence, TMZ can have an indirect role in microglia/macrophage polarisation
changes, with an M2 polarization being supported by different authors [62,63], although
none of them used an IMS schedule. Still, we should also have in mind a possible indirect
effect of TMZ over the lymphocytes anergy status after striking the tumour, which may
superimpose in time with the periodic TMZ administration. One of the goals of our work
was to investigate whether local changes in IMS-TMZ-treated tumours, especially with
respect to immune system, would be related to MRSI-detected spectral pattern changes,
as previously proposed [24,25,31]. The cancer immune cycle involves several cellular
populations and local factors. However, in order to be detected by MRSI-based approaches
(i.e., to significantly contribute to the spectral pattern), these cellular populations must
represent a significant proportion of the tumour volume. Hence, the GAM population is a
suitable candidate to be at least partially responsible for the observed changes, since they
are the most common non-tumoural cell within GB masses, reaching values up to 30–40%
of the overall volume [5]. Other cellular populations such as lymphocytes would represent
only a small fraction of the GB mass volume (ca 1% in GL261 GB, unpublished GABRMN
data) and may not have a direct impact in spectral pattern changes.
4.2. Not All GAMs Are Equal (I): Polarisation of Microglia/Macrophages and Its Role in Therapy
Response in GB
In the majority of solid tumours, progression is associated with a phenotype preva-
lence changing from M1 to M2 [64], which can trigger the suppression of effector T cell
immunity, improved tumour cell survival, promotion of angiogenesis, and chemoresis-
tance [65]. In this sense, we assessed the GAM polarisation profile when GL261 tumours
showed a clear MRSI-detected responding pattern and compared them with untreated
control tumours. Our goal was to better understand the oscillatory behaviour of the
MRSI-detected pattern in terms of a transient/permanent response to therapy in GL261
GB [24,31].
Our studies with Nos2 and CD206 gene markers suggest, first, that both control and
IMS-TMZ-treated tumours contain M1 and M2 microglia/macrophages (Figure 3A,B),
in line with data for control GL261 tumours described in [66]. More interestingly, our
results point to a significantly higher ratio of M1/M2 microglia/macrophage content in
IMS-TMZ-treated responding tumours (Figure 3C), being ca. 2.3-fold times higher than
in control tumours. This result indicates a phenotype switch of GAM from M2 to M1 in
responding tumours compared to control tumours. In other words, more cells infiltrating
the tumour with the ability to start and sustain inflammatory responses and to exhibit
antitumour activity and leading to tumour tissue disruption. This specific M1/M2 ratio
was also evaluated by other authors in various cancer tumour types and in relation to
outcome prognosis. For example, high content of M1 macrophages was associated with
best prognosis in treated ovarian cancer patients, suggesting a correlation between efficacy
of antineoplastic regimens and M1 polarisation [67]. On the other hand, authors in [68]
studied the prevalence of M2-polarised macrophages in different lung neoplastic lesions,
with high M2 infiltration predicting poor prognosis. In lung adenocarcinomas, 79.71%
of tumour-associated macrophages were M2 polarised and the remaining 20.35% were
M1 polarised [68]. Regarding brain tumour-related studies, investigation with clinical
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glioma samples have found an association between high CD163+ cells (M2 marker) and
glioma progression [69]. In the same line, authors in [37] have found that predominant M1
polarisation was associated with better overall prognosis of GB patients, using CXCL10 and
CCL13 as markers for M1 and M2 macrophages, respectively. Moreover, the M1/M2 ratio
was described to be correlated with survival rate in GB patients after TMZ treatment [70].
Further work reported in [71] revealed mixed profiles of M1 and M2 macrophages in
human GB while the ratio M1/M2 correlated with survival in IDH1 wild type GB. It is
then clear that achieving suitable M1/M2 ratios is desirable and will be determinant for
outcome in preclinical and clinical GB.
4.3. Not All GAMs Are Equal (II): The Polarisation Status of Microglia/Macrophages Affects Their
Metabolomic Pattern
It has been described that microglia/macrophage polarisation implies metabolic
changes, involving pathways such as glycolysis, the Krebs cycle, and fatty acid metabolism,
enabling the specialised activities of these cells [72,73]. Furthermore, changes in key
metabolic regulatory events in microglia/macrophages can be initiated in response to
changes in the tumour microenvironment [74]. In relation to this, M1 macrophages
rely on glycolysis for energy production, while M2 macrophages mostly use mitochon-
drial oxidative metabolism (Krebs cycle) for ATP biogenesis. This entails that M1 mi-
croglia/macrophages increase lactate release and fatty acid synthesis, while the synthe-
sis of N-acetyl group-containing compounds, glutamine, glycine, and alanine, among
others, is upregulated in the M2 microglia/macrophage population [11,72,75,76]. Be-
sides, the differential induction of fatty acid synthesis and fatty acid oxidation elicits
microglia/macrophage polarisation towards M1 or M2 profiles, respectively [11].
The different metabolic pathways should contribute, at least partially, to the differen-
tial metabolomic pattern detected in vivo by MRSI-based analyses in GL261 GB transiently
responding to therapy compared with control, untreated tumours. In this respect, the
prototypical source of TMZ-responding tumours [23] shows large amounts of mobile
lipids/lactate (1.33 ppm signal) and increased lactate at 4.1 ppm, combined with higher
polyunsaturated fatty acids (PUFA, 2.8 ppm signal) and other changes in the glutamine,
glutamate, and alanine regions, which would be consistent with the metabolic profiles
expected for the M1 subtype compared to the M2 subtype (e.g., higher lactate in M1s),
related to the limitation of pyruvate entrance into the Krebs cycle triggering formation of
high amounts of lactate from pyruvate [77]).
However, more detailed studies will be needed to further assess the actual impact
of metabolic changes related to microglia/macrophage polarization on the in vivo MRSI
differential metabolomic pattern. In this respect, it is worth remembering that the tumour
spectroscopic pattern also contains contributions from tumour cells and extracellular
metabolites/macromolecules/lipids present in the tumour microenvironment in suitable
concentration to be detected by MRSI. In any case, the MRSI-based nosological images
and the changes in spectral pattern (sources) behind those images seem to be coherent
with changes in M1/M2 ratios. This reinforces the potential of those images for early
in vivo detection of whether a certain therapeutic approach is properly eliciting efficient
host immune response against GB tumours.
Finally, we may also consider that literature describes M2 macrophages being able
to re-polarise to M1, but not the reverse; M1 macrophages are mostly consumed during
the inflammatory response [78]. Then, after a first “wave” of macrophage M1 polarisation
and tumour cell killing, probably driven by interaction with T-cells [9], M1 sub-population
decrease would bring down M1/M2 ratios, close to levels found in untreated actively pro-
liferating tumours. Figure S3 combines a hypothetic scheme of events taking place during
IMS-TMZ therapy in GL261 GB demonstrated in this work (GAM changes, M1/M2 polari-
sation) with the corresponding changes in the MRSI-based nosological images described in
previous work [23–25,31] and used here to select adequate time points for sampling. Its
potential relevance for translational studies is also highlighted there.
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4.4. PD-L1 Gene Expression in GL261 GB
PD-L1 expression level is considered a major positive prognostic biomarker for im-
mune therapy in many cancers, but not yet in glioma [79]. The expression and subcellular
distribution of PD-L1 in the tumour tissue exhibits great variability reflecting the specifici-
ties of cellular and structural microenvironment in the brain, preventing the confident use
of PD-L1 as a prognostic biomarker in glioma [80].
Results obtained in the present work have assessed the PD-L1 gene level expression
in IMS-TMZ-treated and vehicle-treated GL261 GB groups. A significantly higher PD-L1
gene expression (2.3-fold) was found in responding TMZ-treated tumours compared to un-
treated ones. Chemotherapy has been described to modify the tumour microenvironment,
increasing PD-L1 expression [81,82], and our previous work with Western-blot analysis for
control, treated-relapsing, and unresponsive data from GL261 GB samples [31] seems to
partially agree with those results. This is in line with results described by authors in [83],
who also suggested that PD-L1 increase was related to STAT3 signalling. Furthermore, a
significant positive correlation was found between PD-L1 gene expression level and the
M1/M2 ratio (see Figure 4B and Figure S2C), indicating that increased PD-L1 content could
be associated with increased M1-polarised macrophages.
PD-L1 is known to be expressed in a variety of cell types, including macrophages.
For example, a study of patient GB samples showed that monocytes cultured in glioma-
conditioned medium expressed high levels of PD-L1 [84]. The role of PD-L1 in tumour
cells and macrophages seems to be different, though. An interesting study with murine
melanoma and breast cancer cells by Singhal et al. [85] showed that only PD-L1 on tar-
get tumour cells clearly inhibited the effector functions of T cells. PD-L1 expressed by
macrophages exerted a regulatory role only during the interaction of macrophages present-
ing tumour antigen to effector T cells. Thus, in this case PD-L1 could be simply limiting
excessive activation of T cells and protecting PD-L1 harbouring macrophages from being
killed by approaching T cells [85]. In short, available evidence indicates that PD-L1 from
both tumour cells and microglia/macrophages is relevant for assessing prognosis [86]. In
our case, the origin of the reported PD-L1 expression level changes is still unclear, since
samples analysed contain both tumour cells and GAMs and further studies will be needed
for better clarification of this extreme.
4.5. Wrap-up: Incoporating the Measured Gene Expression Results into the Explanation of the
Oscillatory Behaviour of the MRSI-Based Biomarker of Response
In longitudinal studies of IMS-treated response assessment, we have reported periodic
oscillations of the MRSI-based biomarker showing increases in the detected response level
(TRI) every 6 days. In this sense, we also assume that there are tissue events/changes that
originate this oscillation, alternating a high response nosological image profile with periods
showing tissue characteristics that resemble more an actively proliferating tumour.
Figure S3 summarises how we correlate cellular/molecular events taking place with
results obtained in this work. At the therapy starting point, GL261 GB tumours display an
essentially protumoural microglia/macrophage phenotype, supported by qPCR results
and encoded in the red colour over the tumour mass of the nosological images. TMZ
therapy may lead to release/exposure of immunogenic signals [53], which set the cancer
immunity cycle [59]. In the meanwhile, both M1 and M2 populations increase (see also
Figure 2A): M1 microglia/macrophages will participate in tumour cell killing [9], and M2
microglia/macrophages are waiting for M1 polarisation. The M1/M2 ratio changes towards
higher values in tumours showing transient response to IMS-TMZ (Figure 3C). Maximum
response is spotted by our noninvasive biomarker (green colour in nosological images) after
ca. 6 days of therapy administration, in line with the length of the immune cycle described
in [32]. At this point, an increase in PD-L1 gene expression is observed (Figure 4A),
although its origin could be either in tumour cell population, microglia/macrophages
or both together. Since M1 microglia/macrophages are mostly consumed during the
antitumour response events, after such interval, the ratio M1/M2 may shift towards the
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control values, T lymphocytes may be approaching exhaustion, and surviving tumour
cells may start proliferating again leading to tumour regrowth (day +9, red colour over the
tumour image) until the previous therapeutic administration point (at day +6) resets the
immune cycle and produces the next response oscillation (day +12).
Having this hypothesis in mind, how can we obtain an advantage regarding this
biomarker? It is worth noting that therapy can modulate/change macrophage profiles
towards an inflammatory M1 profile with satisfactory results, as already described in
preclinical GB models using amphotericin B [87], CSF-1R inhibition [88], immunovirother-
apy [89], or recombinant adeno-associated virus [90], although the latter presented only
modest result in phase II clinical phases [91]. On the other hand, work described in [92]
focused into blocking relevant pathways in protumoural macrophages with minocycline in
preclinical murine GB models. Our results suggest that our imaging biomarker findings
are at least partially explained by changes in microglia/macrophage profiles within brain
tumours (hence, in the expected antitumour/protumour actions). Thus, we may be able,
in a near future, to follow-up different therapies and foresee results in an early fashion
gathering hints about the prevailing macrophage population at a given moment. A word
of caution may be issued here, since the mutational load of GL261 [93] is much higher
than untreated human GB [94] and this could be a determinant for host immune system
eliciting. In this respect, relapsing human GB contain a similar mutational load [95] to
GL261 tumours. Further confirmation of the potential of such imaging biomarker in human
GB therapy response follow-up may be worthwhile to investigate.
5. Conclusions
Our results confirm that TMZ administered in an immune-enhancing metronomic
schedule increases the GB-associated microglia/macrophage population infiltrating the
tumour. The M2/GAMs ratio was shown to be remarkably lower in responding IMS-
TMZ-treated mice, while the M1/M2 ratio was significantly higher when compared to
vehicle-treated mice. These results indicate that TMZ treatment applied in IMS protocols
contributes to immune system activation, suggesting M2-to-M1 polarisation, improving the
anti-tumoural response mediated by microglia/macrophages. Since it is well known that
GAMs can represent 30–40% of cells in GB and M1 and M2 microglia/macrophages have
different metabolic profiles, this relative population change could be one of the reasons for
the differential MRSI-sampled pattern during response to therapy reinforcing its proposed
role as immune system activity biomarker for future work.
It remains unclear whether the increase of the PD-L1 gene level expression in the
responding IMS-TMZ-treated tumours originates from changes in tumour cells, the M1/M2
microglia/macrophages polarisation, or both. Further studies will be needed to assess the
relative roles of the two cell types in the detected increase of the PD-L1 expression upon
response to therapy in the GL261 GB.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cancers13112663/s1, Table S1: Description of IMS-TMZ and IMS-vehicle treated mice,
including tumour volume at therapy start point and at endpoint, euthanasia day and percentage of
TRI shown at that time; Figure S1: Summary of steps performed for nosological images calculation
mentioned in this work; Figure S2: Pearson correlation analysis between F4/80 gene expression
level and (A) Nos2 and (B) CD206 gene expression levels; and between (C) PD-L1 gene expression
level and M1/M2 ratio (see section 3.4. of the main manuscript for definition) in IMS-TMZ-treated
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line). P values for each group are indicated in the graphs; Figure S3: Hypothetical scheme for the
rationale behind changes in the nosological images coding for response in MRSI of IMS-TMZ treated
GB GL261 bearing mice (see main text for further details).
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